(A) NKG2A and (B) NKG2C expression on NK cells in subjects with AS and HCs. The upper figure represents % of NK positive cells; the lower figure represents.

Slides:



Advertisements
Similar presentations
Monthly improvements in paid work productivity: ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) subpopulations (employed.
Advertisements

Monthly improvements in family, social and leisure activities to week 96 (last observation carried forward imputation). Assessed using the arthritis-specific.
The genomic region spanning rs shows enhancer activity.
Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with systemic sclerosis. Indicated points resemble.
Flow cytometry analysis of HLA-B27 and HLA-B7 transduced cells.
Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.
Percentage of patients achieving EULAR response
p75NTR, TrkA and sortilin expression levels in patients with JIA
Increased frequency of human leukocyte antigen–E inhibitory receptor CD94/NKG2A– expressing peritoneal natural killer cells in patients with endometriosis 
ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.
Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.
VEGF is upregulated in the arterial wall of patients with biopsy-proven GCA but not in controls. VEGF is upregulated in the arterial wall of patients with.
Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.
Change over time in ossification of the posterior longitudinal ligament (OPLL)-like ectopic ossification in individual Enpp1ttw/ttw mice reported in figure.
ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.
Frequency of patients in flare at each time point over 3 months
Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.
P75NTR and disease severity (A) in persistent oligoarticular (n=29), extended oligoarticular (n=16) and polyarticular (n=13) patients p75NTR mRNA expression.
The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.
Ratings of core domains stratified by stakeholder group in the second Delphi round. Ratings of core domains stratified by stakeholder group in the second.
Effect of collagen-induced arthritis (CIA) and 3,4-dichloropropionaniline (DCPA) on osteoclast bone interface density determined by ATPa3 (TCIRG) labelling,
(A) HLA-E expression on the surface of CD14+ cells in patients with AS, HLA-B*2705, HLA-B*2709-positive and HLA-B27-negative HCs. Results are expressed.
Factors influencing the relationship between disease activity (as measured with the ASDAS) and radiographic progression (as measured with the 2-year mSASSS.
Serum levels of (A), human β defensin-2 (hBD-2) and (B), lipocalin-2 (LCN-2) in active full-blown ankylosing spondylitis (AS, n=21) versus healthy controls.
(A) Reduction of circulating stromal cell-derived factor (SDF)-1 levels over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis.
Core type 1 interferon (IFN-1)-associated genes are more highly expressed in myeloid subsets. Core type 1 interferon (IFN-1)-associated genes are more.
Relationships between the baseline disease activity scores and scintigraphic sum scores for the patients with RA, pSpA and axSpA. Relationships between.
IFN and neutrophil gene expression studies.
2/A Comparison of IP-10 and SIGLEC1 levels in healthy donors (HD), patients with glandular (gl.) and extraglandular (egl.) pSS and SLE 2/A. 2/A Comparison.
Different scenarios that explain the effect that an external factor (here occupational activity—blue collar vs white collar—used as an example) could hypothetically.
Osteogenesis in monolayer HLA-B27 transduced hPDCs.
The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.
Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.
Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.
Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.
Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.
Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.
Graphical display for QUADAS-2 results.
(A–D). (A–D). B-cell and Ig changes. Mean changes in total CD3-CD20+ B-cells (A) and immunoglobulin (Ig) subclasses levels (B-D) were measured over 24 weeks.
Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.
JSN and SvdH damage and progression scores with and without the CMC3-5 joints. JSN and SvdH damage and progression scores with and without the CMC3-5 joints.
Results from the second Delphi step showing the percentage of rated domains that the experts agreed on as domains for the annual systemic assessment of.
Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.
Employment of patients with AS compared with controls, by BASDAI
ACR20/50/70 response rates at week 24 (TP1 per-protocol set).
MRI, STIR sequence of sacroiliac joints (SIJs): minimal localised signal increase on both sides of the upper part of the left SIJ (arrows), which does.
Characteristics of the included trials on non-pharmacological treatment. Characteristics of the included trials on non-pharmacological treatment. ASDAS,
The thickness of the subchondral bone plate for healthy subjects and patients with osteoarthritis (OA). The thickness of the subchondral bone plate for.
Serum sRANKL and OPG levels in healthy donors and patients with RA at baseline and after MTX and low-dose prednisolone treatment. Serum sRANKL and OPG.
Monthly improvements in home productivity: ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) subpopulations (last observation.
Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.
Subject disposition through week 156 of treatment
Mean (SE) maximum urinary uric acid excretion rate (mg/hour) following verinurad doses in combination with febuxostat 40 or 80 mg vs febuxostat 40 or 80 mg.
Efficacy as first, second and third bDMARD in patients with axial spondyloarthritis. ASAS, Assessment of Spondylo Arthritis international Society; BASDAI,
Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;
Satisfaction with control of RA
Flowchart of literature revision to identify current available clinical practice guidelines (CPGs) specifically addressed to Ehlers-Danlos Syndromes (EDS)
Classification tree with the selected characteristics.
Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.
Patient disposition over the 52-week study period
Joint pain location and severity.
Graphical representation of the content of the Social Role Participation Questionnaire (SRPQ), which assesses several dimensions of role participation.
Percent of patients with ASDAS inactive disease grouped by normal or elevated CRP at baseline through week 156. §p
Improvement in BASDAI score in patients with normal or elevated CRP at baseline through week 156. *p
Limits of agreement between mean right and mean left tympanic membrane temperatures in 23 healthy, afebrile children (mean of all children). Limits of.
Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.
Relation of P-gp+CD69+CD4+ cells with outcome of intensive immunosuppressive therapy in patients with active proliferative lupus nephritis (LN). Relation.
Serum osteopontin (sOPN) concentrations in patients with giant cell arteritis and healthy controls. (A) sOPN concentrations in active patients with giant.
Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)
Distribution of points (%) across the ESSDAI domains in patients with neurological involvement and in those with non-neurological systemic involvement.
Presentation transcript:

(A) NKG2A and (B) NKG2C expression on NK cells in subjects with AS and HCs. The upper figure represents % of NK positive cells; the lower figure represents cell surface density of receptor expression (ABC units). (A) NKG2A and (B) NKG2C expression on NK cells in subjects with AS and HCs. The upper figure represents % of NK positive cells; the lower figure represents cell surface density of receptor expression (ABC units). Horizontal lines represent the median values. Statistical differences were observed between NKG2A and NKG2C percentages of positive cells in all different cohorts (upper panel). The inhibitory receptor NKG2A also showed a higher cell surface density compared with the activator receptor NKG2C, reaching statistical significance in patients with AS (p=0.02) and B*2705 HCs (p=0.007) (lower panel). No differences were observed comparing the different cohorts of subjects. p<0.001=***0.001 to 0.01=**0.01 to 0.05=* . ABC, antibody binding capacity; AS, ankylosing spondylitis; HC, healthy control; NK, natural killer. Alberto Cauli et al. RMD Open 2018;4:e000597 Copyright © BMJ Publishing Group & EULAR. All rights reserved.